Concepts (279)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 33 | 2023 | 122 | 7.110 |
Why?
|
| Sarcoma | 15 | 2023 | 72 | 2.750 |
Why?
|
| Soft Tissue Neoplasms | 7 | 2022 | 27 | 1.800 |
Why?
|
| Bone Substitutes | 8 | 2017 | 9 | 1.560 |
Why?
|
| Giant Cell Tumor of Bone | 5 | 2022 | 15 | 1.560 |
Why?
|
| Sarcoma, Ewing | 3 | 2020 | 6 | 1.400 |
Why?
|
| Bone Transplantation | 7 | 2017 | 196 | 1.170 |
Why?
|
| Calcium Sulfate | 6 | 2012 | 8 | 1.060 |
Why?
|
| Musculoskeletal Diseases | 2 | 2015 | 35 | 0.910 |
Why?
|
| Humans | 60 | 2023 | 22848 | 0.890 |
Why?
|
| Limb Salvage | 5 | 2023 | 11 | 0.880 |
Why?
|
| Retrospective Studies | 27 | 2023 | 3062 | 0.830 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 175 | 0.810 |
Why?
|
| Leiomyosarcoma | 1 | 2021 | 8 | 0.710 |
Why?
|
| Adult | 23 | 2022 | 6584 | 0.700 |
Why?
|
| Osteosarcoma | 8 | 2021 | 33 | 0.680 |
Why?
|
| Calcium Phosphates | 2 | 2012 | 17 | 0.670 |
Why?
|
| Hip Joint | 2 | 2016 | 519 | 0.660 |
Why?
|
| Adolescent | 15 | 2021 | 1775 | 0.650 |
Why?
|
| Child, Preschool | 9 | 2021 | 489 | 0.640 |
Why?
|
| Young Adult | 12 | 2021 | 1721 | 0.640 |
Why?
|
| Fractures, Bone | 2 | 2012 | 68 | 0.630 |
Why?
|
| Synovitis, Pigmented Villonodular | 2 | 2016 | 3 | 0.620 |
Why?
|
| Child | 12 | 2021 | 990 | 0.610 |
Why?
|
| Tibia | 2 | 2010 | 231 | 0.590 |
Why?
|
| Treatment Outcome | 16 | 2023 | 2960 | 0.580 |
Why?
|
| Middle Aged | 21 | 2021 | 7555 | 0.570 |
Why?
|
| Male | 25 | 2021 | 12453 | 0.540 |
Why?
|
| Arthroplasty, Replacement, Knee | 5 | 2022 | 585 | 0.530 |
Why?
|
| Chondromatosis, Synovial | 1 | 2016 | 4 | 0.530 |
Why?
|
| Bone Diseases | 2 | 2017 | 24 | 0.510 |
Why?
|
| Internal Fixators | 1 | 2016 | 32 | 0.510 |
Why?
|
| Arthrodesis | 2 | 2014 | 37 | 0.510 |
Why?
|
| Foot | 1 | 2016 | 34 | 0.510 |
Why?
|
| Foreign Bodies | 1 | 2016 | 23 | 0.500 |
Why?
|
| Radiotherapy | 1 | 2016 | 28 | 0.500 |
Why?
|
| Female | 22 | 2021 | 12677 | 0.500 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 30 | 0.500 |
Why?
|
| Acetabulum | 3 | 2016 | 215 | 0.500 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 65 | 0.490 |
Why?
|
| Radius | 2 | 2014 | 25 | 0.470 |
Why?
|
| Knee Prosthesis | 2 | 2008 | 208 | 0.440 |
Why?
|
| Tobramycin | 2 | 2005 | 8 | 0.440 |
Why?
|
| Survival Rate | 5 | 2021 | 270 | 0.430 |
Why?
|
| Biopsy | 6 | 2023 | 181 | 0.410 |
Why?
|
| Arthralgia | 2 | 2011 | 119 | 0.400 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2010 | 31 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 368 | 0.390 |
Why?
|
| Prognosis | 8 | 2023 | 630 | 0.390 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 214 | 0.380 |
Why?
|
| Chondrosarcoma | 4 | 2023 | 42 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2017 | 46 | 0.360 |
Why?
|
| Histiocytosis, Sinus | 1 | 2011 | 3 | 0.360 |
Why?
|
| Talus | 1 | 2011 | 8 | 0.360 |
Why?
|
| Allografts | 4 | 2021 | 203 | 0.360 |
Why?
|
| Follow-Up Studies | 8 | 2022 | 1494 | 0.360 |
Why?
|
| Edema | 1 | 2011 | 24 | 0.350 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 470 | 0.350 |
Why?
|
| Patellar Ligament | 1 | 2010 | 36 | 0.340 |
Why?
|
| Humerus | 3 | 2005 | 105 | 0.330 |
Why?
|
| Prosthesis Failure | 4 | 2022 | 478 | 0.320 |
Why?
|
| Femur | 4 | 2022 | 349 | 0.310 |
Why?
|
| Osteomyelitis | 3 | 2005 | 18 | 0.310 |
Why?
|
| Reoperation | 6 | 2022 | 846 | 0.290 |
Why?
|
| Bone Plates | 1 | 2008 | 44 | 0.290 |
Why?
|
| Aged | 12 | 2021 | 7669 | 0.280 |
Why?
|
| Neoadjuvant Therapy | 5 | 2022 | 50 | 0.280 |
Why?
|
| Cisplatin | 3 | 2017 | 50 | 0.270 |
Why?
|
| Osteogenesis | 1 | 2007 | 96 | 0.260 |
Why?
|
| Arthroplasty, Replacement, Hip | 3 | 2022 | 749 | 0.250 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 4055 | 0.250 |
Why?
|
| Orthopedic Procedures | 3 | 2004 | 282 | 0.240 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2017 | 52 | 0.240 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 138 | 0.230 |
Why?
|
| Curettage | 3 | 2022 | 9 | 0.230 |
Why?
|
| Immunohistochemistry | 4 | 2011 | 305 | 0.230 |
Why?
|
| Transplantation, Homologous | 2 | 2004 | 238 | 0.220 |
Why?
|
| Infant | 3 | 2021 | 449 | 0.220 |
Why?
|
| Margins of Excision | 2 | 2022 | 27 | 0.220 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 81 | 0.220 |
Why?
|
| Pelvic Bones | 1 | 2004 | 16 | 0.220 |
Why?
|
| Joint Instability | 1 | 2008 | 363 | 0.210 |
Why?
|
| Knee Joint | 2 | 2008 | 688 | 0.210 |
Why?
|
| Spinal Neoplasms | 1 | 2023 | 33 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2015 | 588 | 0.200 |
Why?
|
| Embolization, Therapeutic | 1 | 2023 | 41 | 0.200 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 62 | 0.200 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 307 | 0.200 |
Why?
|
| Prostheses and Implants | 2 | 2015 | 139 | 0.200 |
Why?
|
| Neutrophils | 1 | 2023 | 85 | 0.200 |
Why?
|
| Plasma Gases | 1 | 2022 | 2 | 0.200 |
Why?
|
| Apoptosis | 5 | 2022 | 172 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2021 | 509 | 0.190 |
Why?
|
| Absorbable Implants | 1 | 2002 | 26 | 0.190 |
Why?
|
| Sarcoma, Synovial | 1 | 2022 | 6 | 0.190 |
Why?
|
| Vancomycin | 1 | 2002 | 51 | 0.190 |
Why?
|
| Bone Cements | 3 | 2022 | 82 | 0.190 |
Why?
|
| Radiography | 5 | 2015 | 549 | 0.190 |
Why?
|
| Debridement | 2 | 2012 | 97 | 0.180 |
Why?
|
| Lymphatic Vessels | 1 | 2021 | 9 | 0.180 |
Why?
|
| Myxosarcoma | 1 | 2020 | 3 | 0.170 |
Why?
|
| Fibrosarcoma | 1 | 2020 | 4 | 0.170 |
Why?
|
| Hemipelvectomy | 1 | 2020 | 2 | 0.170 |
Why?
|
| Pelvic Neoplasms | 1 | 2020 | 9 | 0.170 |
Why?
|
| Orthopedics | 1 | 2002 | 104 | 0.170 |
Why?
|
| Hip Prosthesis | 2 | 2022 | 508 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 18 | 0.160 |
Why?
|
| Prosthesis-Related Infections | 1 | 2022 | 182 | 0.160 |
Why?
|
| Antineoplastic Agents | 3 | 2017 | 155 | 0.160 |
Why?
|
| Cell Line, Tumor | 7 | 2017 | 218 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 8 | 0.150 |
Why?
|
| Medically Underserved Area | 1 | 2019 | 13 | 0.150 |
Why?
|
| Dogs | 4 | 2007 | 136 | 0.150 |
Why?
|
| Medical Oncology | 1 | 2019 | 31 | 0.150 |
Why?
|
| Chemoradiotherapy | 1 | 2019 | 55 | 0.150 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 59 | 0.150 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 78 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2019 | 100 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2019 | 76 | 0.140 |
Why?
|
| Osteoarthritis | 1 | 2022 | 308 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 187 | 0.140 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 37 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.140 |
Why?
|
| Imidazoles | 1 | 2017 | 51 | 0.130 |
Why?
|
| Piperazines | 1 | 2017 | 64 | 0.130 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2016 | 10 | 0.130 |
Why?
|
| Synovectomy | 1 | 2016 | 5 | 0.130 |
Why?
|
| Chondroma | 3 | 2012 | 6 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2021 | 1621 | 0.120 |
Why?
|
| Child Development | 1 | 2016 | 65 | 0.120 |
Why?
|
| Time Factors | 3 | 2022 | 1220 | 0.120 |
Why?
|
| Disease Management | 1 | 2016 | 82 | 0.120 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 4 | 0.120 |
Why?
|
| Prosthesis Design | 3 | 2022 | 448 | 0.120 |
Why?
|
| Prosthesis Implantation | 1 | 2015 | 23 | 0.120 |
Why?
|
| Radiotherapy Dosage | 1 | 2015 | 64 | 0.120 |
Why?
|
| Supination | 1 | 2014 | 10 | 0.120 |
Why?
|
| Risk Factors | 2 | 2022 | 1942 | 0.120 |
Why?
|
| Ossification, Heterotopic | 1 | 2015 | 28 | 0.120 |
Why?
|
| Lung | 1 | 2015 | 142 | 0.110 |
Why?
|
| Wrist Joint | 1 | 2014 | 21 | 0.110 |
Why?
|
| Hand Strength | 1 | 2014 | 34 | 0.110 |
Why?
|
| Arthroplasty | 1 | 2016 | 146 | 0.110 |
Why?
|
| Cartilage, Articular | 2 | 2016 | 389 | 0.110 |
Why?
|
| Drug Implants | 2 | 2005 | 8 | 0.110 |
Why?
|
| Protein Kinases | 1 | 2014 | 12 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 947 | 0.110 |
Why?
|
| Telomerase | 2 | 2004 | 9 | 0.110 |
Why?
|
| Spinal Fusion | 1 | 2020 | 435 | 0.110 |
Why?
|
| Receptors, Notch | 1 | 2013 | 1 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2012 | 260 | 0.100 |
Why?
|
| Wnt Proteins | 1 | 2013 | 16 | 0.100 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 105 | 0.100 |
Why?
|
| beta Catenin | 1 | 2013 | 40 | 0.100 |
Why?
|
| Animals | 5 | 2007 | 3025 | 0.100 |
Why?
|
| Bone Matrix | 2 | 2003 | 17 | 0.100 |
Why?
|
| Bone Cysts | 1 | 2012 | 1 | 0.100 |
Why?
|
| Fibrous Dysplasia of Bone | 1 | 2012 | 3 | 0.100 |
Why?
|
| Injections, Intralesional | 1 | 2012 | 30 | 0.100 |
Why?
|
| Bone Regeneration | 2 | 2003 | 64 | 0.100 |
Why?
|
| Diagnosis, Differential | 2 | 2011 | 287 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 34 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2022 | 36 | 0.090 |
Why?
|
| Range of Motion, Articular | 1 | 2014 | 643 | 0.090 |
Why?
|
| Ankle | 1 | 2011 | 20 | 0.090 |
Why?
|
| Thoracoscopy | 1 | 2010 | 19 | 0.090 |
Why?
|
| Ilium | 1 | 2010 | 29 | 0.090 |
Why?
|
| Age Factors | 2 | 2019 | 657 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 270 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 377 | 0.080 |
Why?
|
| Chicago | 1 | 2012 | 808 | 0.080 |
Why?
|
| Survival Analysis | 1 | 2008 | 210 | 0.070 |
Why?
|
| Compressive Strength | 1 | 2007 | 18 | 0.070 |
Why?
|
| Elasticity | 1 | 2007 | 28 | 0.070 |
Why?
|
| Injections | 1 | 2007 | 32 | 0.070 |
Why?
|
| Illinois | 1 | 2008 | 211 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2023 | 1528 | 0.070 |
Why?
|
| Cell Division | 3 | 2022 | 72 | 0.070 |
Why?
|
| Muscle Proteins | 1 | 2006 | 26 | 0.070 |
Why?
|
| Radiation Tolerance | 1 | 2006 | 6 | 0.060 |
Why?
|
| Glycoproteins | 1 | 2006 | 44 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 92 | 0.060 |
Why?
|
| Proteins | 1 | 2006 | 55 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2006 | 29 | 0.060 |
Why?
|
| Carrier Proteins | 1 | 2006 | 82 | 0.060 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 11 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 259 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2016 | 122 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 274 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 2 | 2021 | 77 | 0.060 |
Why?
|
| Blastomycosis | 1 | 2004 | 23 | 0.050 |
Why?
|
| Mutation | 2 | 2021 | 284 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2023 | 29 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 99 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2023 | 44 | 0.050 |
Why?
|
| Bone Demineralization Technique | 1 | 2003 | 1 | 0.050 |
Why?
|
| Blood Loss, Surgical | 1 | 2023 | 53 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2023 | 14 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 16 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2023 | 42 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2023 | 102 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2016 | 354 | 0.050 |
Why?
|
| Exoribonucleases | 1 | 2002 | 1 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2002 | 10 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2002 | 13 | 0.050 |
Why?
|
| Necrosis | 1 | 2022 | 21 | 0.050 |
Why?
|
| Bone Resorption | 1 | 2003 | 77 | 0.050 |
Why?
|
| Replantation | 1 | 2022 | 7 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 26 | 0.050 |
Why?
|
| Transplantation Immunology | 1 | 2002 | 3 | 0.050 |
Why?
|
| Arthroscopy | 1 | 2011 | 1042 | 0.050 |
Why?
|
| Forecasting | 1 | 2002 | 85 | 0.050 |
Why?
|
| Printing, Three-Dimensional | 1 | 2021 | 8 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2004 | 485 | 0.050 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2002 | 18 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2022 | 30 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2022 | 45 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 36 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2022 | 72 | 0.050 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 42 | 0.040 |
Why?
|
| Cartilage | 1 | 2002 | 96 | 0.040 |
Why?
|
| SEER Program | 1 | 2021 | 41 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2002 | 361 | 0.040 |
Why?
|
| DNA Damage | 2 | 2014 | 27 | 0.040 |
Why?
|
| Tendons | 1 | 2002 | 190 | 0.040 |
Why?
|
| Biomechanical Phenomena | 1 | 2002 | 582 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 82 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 3 | 2004 | 115 | 0.040 |
Why?
|
| Mesna | 1 | 2019 | 3 | 0.040 |
Why?
|
| Ifosfamide | 1 | 2019 | 5 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 32 | 0.040 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 9 | 0.040 |
Why?
|
| Leg | 1 | 2019 | 43 | 0.040 |
Why?
|
| Arm | 1 | 2019 | 80 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 8 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 27 | 0.030 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 5 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 125 | 0.030 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2014 | 5 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2014 | 5 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 36 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 35 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 67 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2013 | 7 | 0.030 |
Why?
|
| Culture Techniques | 1 | 1992 | 17 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1992 | 39 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1992 | 111 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 42 | 0.020 |
Why?
|
| Acridine Orange | 1 | 2006 | 1 | 0.020 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 5 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2006 | 14 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2006 | 78 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2006 | 57 | 0.020 |
Why?
|
| Cell Survival | 1 | 2006 | 103 | 0.020 |
Why?
|
| Manubrium | 1 | 2004 | 1 | 0.010 |
Why?
|
| Sternoclavicular Joint | 1 | 2004 | 6 | 0.010 |
Why?
|
| Chondrocytes | 1 | 2004 | 147 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 165 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 96 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 227 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2002 | 23 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 2002 | 5 | 0.010 |
Why?
|
| Telomere | 1 | 2002 | 3 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 50 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 94 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2002 | 254 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 477 | 0.010 |
Why?
|
| Sepharose | 1 | 1992 | 4 | 0.010 |
Why?
|
| Hexuronic Acids | 1 | 1992 | 6 | 0.010 |
Why?
|
| Glucuronic Acid | 1 | 1992 | 6 | 0.010 |
Why?
|
| Alginates | 1 | 1992 | 7 | 0.010 |
Why?
|
| Gels | 1 | 1992 | 9 | 0.010 |
Why?
|
| Keratan Sulfate | 1 | 1992 | 14 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1992 | 46 | 0.010 |
Why?
|
| Microspheres | 1 | 1992 | 21 | 0.010 |
Why?
|
| Cattle | 1 | 1992 | 108 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 1992 | 47 | 0.010 |
Why?
|
| Aggrecans | 1 | 1992 | 45 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 1992 | 390 | 0.010 |
Why?
|